Madeleine Wakeling

Madeleine Wakeling has over 19 years of experience in the biotechnology and pharmaceutical industry. Madeleine began their career in 2002 as a Senior Scientist at BioVex, where they developed quality control and characterisation assays for recombinant herpesvirus products. In 2006, they moved to GlaxoSmithKline as a Principal Scientist and Virology Team Leader in Biopharmaceutical Process Development. At GSK, they managed a team of four scientists and contributed to regulatory submissions. In 2009, they joined MedImmune as a CMC Project Manager and was responsible for leading and managing global cross-functional matrix CMC teams. In 2012, they moved to the Medical Research Council Prion Unit as an Immunotherapeutics Project Manager, where they were responsible for leading a cross-functional team developing a novel antibody for Creutzfeldt-Jakob Disease. In 2015, they joined Autolus Ltd. as a Project Director, where they led a cross-functional Product Development Team for the AUTO4/5 programme. In 2018, they joined Crescendo Biologics Limited as the Director of Project Management, where they project managed the lead preclinical programme. In 2021, they joined Cellinta Limited as the Director Programme Management and Transine Therapeutics as the VP Programme Management & Operations.

Madeleine Wakeling has a diverse educational background, having studied Molecular Virology, Molecular Biology, and Project Management. Madeleine obtained their Doctor of Philosophy (PhD) in Molecular Virology from The University of Edinburgh in 2000, following their BSc (Hons) Molecular Biology from the University of Glasgow in 1996. In 2020, they completed a Mini MBA from the London School of Business and Finance LSBF. Most recently, they obtained their Project Management Professional (PMP) certification from the Project Management Institute in 2023.